Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.65 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053523 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL14222418 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL584860 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL649983 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL17112575 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL1394716 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL31128136 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL17112628 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL19741915 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Bicarbonate SCHEMBL9225058 | 0.96 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4554934-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4539937-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | Prelude Therapeutics Incorporated (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119836416-A | KAT6 targeting compounds with ubiquitin ligase binding moiety | 普莱鲁德疗法有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119731160-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023245150-A9 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240417405-A1 | Substituted Spiro Derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-19 | — | — | US | disclosed |
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024015503-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015503-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS, INCORPORATED | 2023-12-28 | — | — | US | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022237627-A1 | SUBSTITUTED SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| CN-110204550-B | Bicyclic compounds as Autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | 豪夫迈·罗氏有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3122750-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015144605-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBP, EBPL, ELP1 | CHRNB2 2145/4885CHRNA4 1506/4885CHRNB4 1266/4885 |
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | KAT6A, KAT6B, KAT2A | CHRNB2 3316/4885CHRNA4 4317/4885CHRNB4 3686/4885 |
| US-20240417405-A1 | Substituted Spiro Derivatives | BMI1, MLLT1, MLLT3 | CHRNB2 4766/4885CHRNA4 4772/4885CHRNB4 4805/4885 |
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | CHRNB2 48/4885CHRNA4 276/4885CHRNB4 57/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | CHRNB2 53/4885CHRNA4 294/4885CHRNB4 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.